-
CHIP in HF: prognostic role and cell-intrinsic effects Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-20 Karina Huynh
Two studies now report that TET2-driven clonal haematopoiesis of indeterminate potential (CHIP) is associated with poor prognosis in patients with heart failure (HF) and preserved ejection fraction and that DNMT3A CHIP driver mutations promote dysregulated gene expression profiles that are associated with inflammation in monocytes in the setting of HF.
-
Migraines and cardiovascular disease: mechanisms and methodological challenges Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-18 Tobias Kurth, Pamela M. Rist
The link between migraine and cardiovascular disease is complex and involves overlapping mechanisms, such as endovascular disturbances. Challenges in measuring migraine, in distinguishing between causation and prediction, and in the understanding of clinical implications highlight the need for further research to guide treatment and cardiovascular risk assessment for the millions of individuals living
-
Semaglutide is beneficial in patients with HFpEF and obesity Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-14 Irene Fernández-Ruiz
In patients with heart failure (HF) with preserved ejection fraction and obesity, treatment with the glucagon-like peptide 1 receptor agonist semaglutide (2.4 mg) leads to large reductions in HF-related symptoms and physical limitations, improves exercise function and decreases body weight compared with placebo, according to the STEP-HFpEF trial.
-
Immunomodulation and immunopharmacology in heart failure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-14 George Markousis-Mavrogenis, Lukas Baumhove, Ali A. Al-Mubarak, Joseph Pierre Aboumsallem, Nils Bomer, Adriaan A. Voors, Peter van der Meer
-
Complete revascularization in MI: role in older patients and optimal timing Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-13 Karina Huynh
The FIRE trial showed that complete revascularization improves outcomes in older patients with myocardial infarction (MI) and multivessel disease compared with culprit-lesion-only revascularization, whereas the MULTISTARS AMI trial reported that immediate multivessel revascularization is non-inferior to staged revascularization in patients with ST-segment elevation MI.
-
Age-induced senescence impairs the neurovascular interface in the heart Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-13 Jennifer Harman
An interaction between blood vessels and nerve fibres in the heart contributes to the decline in nerve density in the ageing left ventricle, potentially increasing susceptibility to arrhythmias.
-
Catheter ablation improves outcomes in patients with AF and end-stage HF Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-11 Karina Huynh
In the CASTLE HTx trial, patients with symptomatic atrial fibrillation and end-stage heart failure who underwent catheter ablation and received medical therapy had improved outcomes compared with patients who received medical therapy only.
-
VA-ECMO does not increase survival in MI-related cardiogenic shock Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-06 Gregory B. Lim
New data from the ECLS-SHOCK trial and a meta-analysis indicate that the routine use of venoarterial extracorporeal membrane oxygenation does not increase survival in patients with myocardial infarction-related cardiogenic shock.
-
New insights into OCT-guided PCI Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-05 Irene Fernández-Ruiz
Two clinical trials presented at the ESC Congress 2023 provide conflicting evidence on the use of optical coherence tomography to guide percutaneous coronary intervention.
-
No benefit of colchicine to prevent AF or myocardial injury after non-cardiac surgery Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-09-04 Gregory B. Lim
According to data from the COP-AF trial, anti-inflammatory therapy with colchicine does not reduce the risk of perioperative atrial fibrillation or myocardial injury in patients undergoing major non-cardiac thoracic surgery.
-
Non-steroidal mineralocorticoid receptor antagonists in heart failure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-29 Gerasimos Filippatos, Dimitrios Farmakis
-
Circadian medicine: a critical strategy for cardiac care Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-29 Michael J. Sole, Tami A. Martino
-
Interatrial shunt devices for heart failure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-25 Finn Gustafsson
Unloading left atrial hypertension by catheter-based, transvenous creation of atrial shunts is being explored to treat heart failure. So far, trials including sham control have demonstrated safety and efficacy in lowering left-sided cardiac filling pressures. Ongoing trials will determine the effect on clinical outcomes.
-
Pitavastatin reduces cardiovascular events in patients with HIV infection Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-16 Karina Huynh
In the REPRIEVE trial, pitavastatin treatment in patients with human immunodeficiency virus (HIV) infection without pre-existing cardiovascular disease prevented cardiovascular events compared with placebo.
-
Heart disease causes sleep disturbances via neuroimmune mechanisms Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-14 Irene Fernández-Ruiz
A new study reveals that the disrupted sleep patterns that are frequently observed in patients with cardiac disease are driven by immune-mediated sympathetic denervation and dysfunction of the pineal gland, which leads to a decrease in the circulating levels of melatonin and subsequent sleep disruption.
-
Animal models to study cardiac regeneration Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-14 Michael Weinberger, Paul R. Riley
-
Valvular heart disease and cardiomyopathy: reappraisal of their interplay Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-10 Nina Ajmone Marsan, Francesca Graziani, Maria Chiara Meucci, Hoi W. Wu, Rosa Lillo, Jeroen J. Bax, Francesco Burzotta, Massimo Massetti, J. Wouter Jukema, Filippo Crea
-
The role of cardiac pericytes in health and disease: therapeutic targets for myocardial infarction Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-04 Elisa Avolio, Paola Campagnolo, Rajesh Katare, Paolo Madeddu
-
Novel macrophage targets for the treatment of atrial fibrillation Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-08-02 Karina Huynh
A study shows that macrophages undergo substantial expansion in the diseased atria of patients with atrial fibrillation (AF), and identifies two potential immunotherapy targets for the treatment of AF.
-
Cholesterol catabolism and bile acid synthesis in cardiomyocytes promote inflammation and heart failure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-31 Gregory B. Lim
In failing cardiomyocytes, depletion of carnitine acetyltransferase promotes cholesterol catabolism via the bile acid synthesis pathway. The intracellular accumulation of bile acid intermediates induces the release of mitochondrial DNA into the cytosol, triggering type I interferon responses and AIM2 inflammasome activation, thereby contributing to chronic myocardial inflammation and heart failure
-
Promising novel siRNA for the treatment of hypertension Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-31 Irene Fernández-Ruiz
Patients with hypertension who receive a single subcutaneous dose of zilebesiran, a novel small-interfering RNA that inhibits hepatic angiotensinogen synthesis, have reductions in serum angiotensinogen levels and 24-h ambulatory blood pressure that last for up to 24 weeks, according to a phase I study.
-
Accelerated reduction in global cardiovascular disease is essential to achieve the Sustainable Development Goals Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-26 Daniel J. Piñeiro, Elisa Codato, Jeremiah Mwangi, Jean-Luc Eiselé, Jagat Narula
-
Unravelling ACS pathophysiology using intracoronary OCT and deep immunophenotyping Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-25 Jennifer Harman
According to two papers from the OPTICO-ACS study, patients with acute coronary syndrome and an intact fibrous cap (plaque erosion), tend to have lower levels of inflammation and better prognosis than patients with rupture of the fibrous cap. In addition, Toll-like receptor 2-mediated neutrophil activation has a key role in plaque erosion.
-
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-20 Diana A. Gorog, Jose Luis Ferreiro, Ingo Ahrens, Junya Ako, Tobias Geisler, Sigrun Halvorsen, Kurt Huber, Young-Hoon Jeong, Eliano P. Navarese, Andrea Rubboli, Dirk Sibbing, Jolanta M. Siller-Matula, Robert F. Storey, Jack W. C. Tan, Jurrien M. ten Berg, Marco Valgimigli, Christophe Vandenbriele, Gregory Y. H. Lip
-
Roadmap on the use of artificial intelligence for imaging of vulnerable atherosclerotic plaque in coronary arteries Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-18 Bernhard Föllmer, Michelle C. Williams, Damini Dey, Armin Arbab-Zadeh, Pál Maurovich-Horvat, Rick H. J. A. Volleberg, Daniel Rueckert, Julia A. Schnabel, David E. Newby, Marc R. Dweck, Giulio Guagliumi, Volkmar Falk, Aldo J. Vázquez Mézquita, Federico Biavati, Ivana Išgum, Marc Dewey
-
Heart transplantation: advances in expanding the donor pool and xenotransplantation Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-14 Stephanie Jou, Sean R. Mendez, Jason Feinman, Lindsey R. Mitrani, Valentin Fuster, Massimo Mangiola, Nader Moazami, Claudia Gidea
-
FGF23 and klotho at the intersection of kidney and cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-13 Daniel Edmonston, Alexander Grabner, Myles Wolf
-
Ruxolitinib is a CaMKII inhibitor that can be repurposed to prevent arrhythmias Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-03 Karina Huynh
The FDA-approved drug ruxolitinib has been identified as an inhibitor of Ca2+/calmodulin-dependent protein kinase II (CaMKII) that has the potential to be repurposed to treat arrhythmias induced by CaMKII hyperactivity.
-
RAPID return to sinus rhythm after SVT using intranasal etripamil Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-07-03 Karina Huynh
In the multicentre, randomized, placebo-controlled RAPID trial, use of symptom-prompted, self-administered, intranasally delivered etripamil was safe and superior to placebo for the conversion of paroxysmal superventricular tachycardia to sinus rhythm.
-
Testosterone-replacement therapy does not increase cardiac events in men with hypogonadism Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-30 Gregory B. Lim
Testosterone-replacement therapy in men with hypogonadism and a high risk of cardiovascular disease does not increase the risk of adverse cardiac events, according to data from the TRAVERSE trial.
-
Low alcohol intake might lower CVD risk by reducing stress-related brain activity Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-26 Irene Fernández-Ruiz
New research shows that the reduced risk of major adverse cardiovascular events associated with light or moderate alcohol consumption is partly mediated by attenuation of the activity of a stress-related neural network.
-
IL-6R antagonism ameliorates atherosclerosis linked to Tet2-related clonal haematopoiesis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-26 Karina Huynh
Liu and colleagues demonstrate the crucial role of IL-6 signalling in the development of atherosclerosis driven by Tet2-related clonal haematopoiesis.
-
Unravelling the genetic heart–brain connection using MRI Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-19 Karina Huynh
Genetic analysis of multiorgan imaging data provided novel insights into the shared biology between the heart and the brain.
-
International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-15 Gerald F. Watts, Samuel S. Gidding, Robert A. Hegele, Frederick J. Raal, Amy C. Sturm, Laney K. Jones, Mitchell N. Sarkies, Khalid Al-Rasadi, Dirk J. Blom, Magdalena Daccord, Sarah D. de Ferranti, Emanuela Folco, Peter Libby, Pedro Mata, Hapizah M. Nawawi, Uma Ramaswami, Kausik K. Ray, Claudia Stefanutti, Shizuya Yamashita, Jing Pang, Gilbert R. Thompson, Raul D. Santos
-
Trained immunity in atherosclerotic cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-15 Niels P. Riksen, Siroon Bekkering, Willem J. M. Mulder, Mihai G. Netea
-
Interplay of hypoxia-inducible factors and oxygen therapy in cardiovascular medicine Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-12 Yafen Liang, Wei Ruan, Yandong Jiang, Richard Smalling, Xiaoyi Yuan, Holger K. Eltzschig
-
Antibody treatment to deplete transthyretin amyloid deposits in the heart Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-07 Gregory B. Lim
An antibody-based therapy for transthyretin amyloid cardiomyopathy is safe, and initial findings from a phase I trial suggest that it might deplete amyloid deposits in the heart.
-
Sacubitril–valsartan shows benefit in heart failure with ejection fraction of >40% Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-07 Irene Fernández-Ruiz
In a diverse population of patients with heart failure with mildly reduced or preserved ejection fraction stabilized after a recent worsening heart failure event, treatment with sacubitril–valsartan induces greater reductions in plasma NT-proBNP levels and is associated with clinical benefit compared with valsartan alone, despite a higher rate of symptomatic hypotension.
-
A fatty acid from mother’s milk drives cardiomyocyte maturation in newborn mice Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-06 Irene Fernández-Ruiz
The essential omega-6 polyunsaturated fatty acid γ-linolenic acid present in maternal milk coordinates cardiac adaptation and survival in newborn mice, according to a new study.
-
Implantable haemodynamic sensor to remotely MONITOR HF Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-06 Gregory B. Lim
Results from the MONITOR-HF trial show that remote monitoring of pulmonary artery pressure using the implantable CardioMEMS sensor in patients with chronic heart failure improves quality of life and reduces hospitalizations.
-
Clinical quantitative coronary artery stenosis and coronary atherosclerosis imaging: a Consensus Statement from the Quantitative Cardiovascular Imaging Study Group Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-05 Aldo J. Vázquez Mézquita, Federico Biavati, Volkmar Falk, Hatem Alkadhi, Reza Hajhosseiny, Pál Maurovich-Horvat, Robert Manka, Sebastian Kozerke, Matthias Stuber, Thorsten Derlin, Keith M. Channon, Ivana Išgum, Adriaan Coenen, Bernhard Foellmer, Damini Dey, Rick H. J. A. Volleberg, Felix G. Meinel, Marc R. Dweck, Jan J. Piek, Tim van de Hoef, Ulf Landmesser, Giulio Guagliumi, Andreas A. Giannopoulos
-
Targeting ALK1 to block LDL transcytosis and halt atherosclerosis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-06-02 Karina Huynh
In a mouse model of atherosclerosis, a selective monoclonal antibody that blocks the binding of LDL to activin receptor-like kinase 1 reduced plaque formation in the aorta.
-
Simvastatin protects against endothelial dysfunction via epigenetic mechanisms Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-26 Irene Fernández-Ruiz
Simvastatin improves endothelial cell function by inhibiting endothelial-to-mesenchymal transition through an epigenetic regulatory mechanism, according to a new study.
-
Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-26 Julia Ritterhoff, Rong Tian
-
Global epidemiology of acute coronary syndromes Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-25 Adam Timmis, Denis Kazakiewicz, Nick Townsend, Radu Huculeci, Victor Aboyans, Panos Vardas
-
Flow-induced reprogramming of endothelial cells in atherosclerosis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-24 Ian A. Tamargo, Kyung In Baek, Yerin Kim, Christian Park, Hanjoong Jo
-
Identifying leukocyte phenotypes by scRNA-seq to predict cardiovascular risk Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-22 Johannes Gollmer, Andreas Zirlik
-
Young women with AMI have worse outcomes than men up to 1 year after discharge Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-17 Karina Huynh
Findings from the VIRGO study reveal that young women with acute myocardial infarction are more likely to be rehospitalized within 1 year compared with similarly aged men.
-
Aggregation of big tau disrupts microtubules and causes diastolic dysfunction Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-17 Gregory B. Lim
Hyperphosphorylation of tau in the heart reduces the tyrosination of microtubules, leading to myocardial stiffness and heart failure. This novel mechanism of diastolic dysfunction parallels the aggregation of tau in the brain that leads to Alzheimer disease and might be amenable to treatment using monoclonal antibodies against tau.
-
Hallmarks of cardiovascular ageing Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-16 Mahmoud Abdellatif, Peter P. Rainer, Simon Sedej, Guido Kroemer
-
Cardiovascular risk in diabetes mellitus: epidemiology, assessment and prevention Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-16 Nathan D. Wong, Naveed Sattar
-
Interventional therapies for pulmonary embolism Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-12 Felix Götzinger, Lucas Lauder, Andrew S. P. Sharp, Irene M. Lang, Stephan Rosenkranz, Stavros Konstantinides, Elazer R. Edelman, Michael Böhm, Wissam Jaber, Felix Mahfoud
-
Clonal haematopoiesis and atherosclerotic cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-11 Herra Ahmad, Siddhartha Jaiswal
-
Mapping the functions of IgM antibodies in atherosclerotic cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-11 Justine Deroissart, Christoph J. Binder
-
Maternal cardiovascular disorders before and during pregnancy and offspring cardiovascular risk across the life course Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-11 Romy Gaillard, Vincent W. V. Jaddoe
-
The contribution of the exposome to the burden of cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-10 Thomas Münzel, Mette Sørensen, Omar Hahad, Mark Nieuwenhuijsen, Andreas Daiber
-
A role for lipophagy in atherosclerosis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-05-09 Thomas Laval, Mireille Ouimet
-
A high-salt diet promotes atherosclerosis by altering haematopoiesis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-04-24 Man K. S. Lee, Andrew J. Murphy
-
AI outperforms sonographers at diagnosing cardiac function on echocardiography Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-04-19 Irene Fernández-Ruiz
An artificial intelligence-guided workflow for initial evaluation of left ventricular ejection fraction in echocardiography is non-inferior to initial assessment by a sonographer, according to findings from a blinded, randomized, non-inferiority clinical trial.
-
The bidirectional association between atrial fibrillation and myocardial infarction Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-04-17 Tanja Charlotte Frederiksen, Christina Catherine Dahm, Sarah R. Preis, Honghuang Lin, Ludovic Trinquart, Emelia J. Benjamin, Jelena Kornej